Additionally, CNS pathology can alter PPAR expression by oligodendrocyte lineage cells. For instance, PPARδ expression is enhanced in OPCs and oligodendrocytes after SCI, suggesting these cells would be responsive to PPAR signaling (Almad and McTigue, 2010). Indeed, activation of PPARγ and PPARδ after SCI decreases lesion area, increases myelination and promotes locomotor activity (McTigue et al., 2007; Park et al., 2007; Paterniti et al., 2010). PPARγ activation also protects myelin in an in vitro model of inflammatory demyelination (Paterniti et al., 2010). Similarly, PPAR activation in the EAE model delays onset and reduces the severity of clinical symptoms (Niino et al., 2001; Diab et al., 2002; Feinstein et al., 2002; Genovese et al., 2005; Gocke et al., 2009).
